Anthony Quinn Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Anthony Quinn.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Anthony Quinn. Anthony Quinn is EVP, CMO & Head of R&D in SYNAGEVA BIOPHARMA CORP ($GEVA) and SVP, Chief Medical Officer in SYNAGEVA BIOPHARMA CORP ($GEVA).
Latest Insider Trading Transactions of Anthony Quinn
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 04 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Option Exercise | M | 23.00 | 10,000 | 230,000 | 30,000 | |
| Sep 04 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Sell | S | 72.88 | 300 | 21,864 | 25,595 | 25.9 K to 25.6 K (-1.16 %) |
| Sep 04 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Sell | S | 71.96 | 700 | 50,372 | 25,895 | 26.6 K to 25.9 K (-2.63 %) |
| Sep 04 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Sell | S | 70.50 | 400 | 28,200 | 26,595 | 27 K to 26.6 K (-1.48 %) |
| Sep 04 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Sell | S | 69.88 | 8,600 | 600,968 | 26,995 | 35.6 K to 27 K (-24.16 %) |
| Sep 04 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Buy | M | 23.00 | 10,000 | 230,000 | 35,595 | 25.6 K to 35.6 K (+39.07 %) |
| Jul 02 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Grant | A | 54.89 | 71 | 3,897 | 25,595 | 25.5 K to 25.6 K (+0.28 %) |
| Jun 05 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Option Exercise | A | 80.35 | 45,000 | 3,615,750 | 45,000 | |
| Apr 03 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Option Exercise | M | 0.95 | 10,000 | 9,500 | 18,964 | |
| Apr 03 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Buy | M | 0.95 | 10,000 | 9,500 | 25,524 | 15.5 K to 25.5 K (+64.42 %) |
| Apr 03 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Option Exercise | M | 23.00 | 10,000 | 230,000 | 40,000 | |
| Apr 03 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Option Exercise | M | 0.95 | 10,000 | 9,500 | 28,964 | |
| Apr 03 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Sell | S | 85.76 | 1,050 | 90,048 | 15,524 | 16.6 K to 15.5 K (-6.34 %) |
| Apr 03 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Sell | S | 84.72 | 4,746 | 402,081 | 16,574 | 21.3 K to 16.6 K (-22.26 %) |
| Apr 03 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Sell | S | 83.50 | 3,529 | 294,672 | 21,320 | 24.8 K to 21.3 K (-14.20 %) |
| Apr 03 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Sell | S | 82.80 | 10,675 | 883,890 | 24,849 | 35.5 K to 24.8 K (-30.05 %) |
| Apr 03 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Buy | M | 23.00 | 10,000 | 230,000 | 35,524 | 25.5 K to 35.5 K (+39.18 %) |
| Apr 03 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Buy | M | 0.95 | 10,000 | 9,500 | 25,524 | 15.5 K to 25.5 K (+64.42 %) |
| Jan 02 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Grant | A | 36.30 | 192 | 6,970 | 15,524 | 15.3 K to 15.5 K (+1.25 %) |
| Jul 01 2013 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | SVP, Chief Medical ... | Grant | A | 35.68 | 297 | 10,597 | 15,332 | 15 K to 15.3 K (+1.98 %) |
| Jun 10 2013 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | SVP, Chief Medical ... | Option Exercise | A | 40.32 | 45,000 | 1,814,400 | 45,000 |
Page: 1